Xiaoxiang Chen, MD,PhD
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Xiaoxiang
AVANIRA3, NCT04556071: Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Recruiting
2
32
RoW
Niraparib, Zejula, Bevacizumab, Avastin
Xiaoxiang Chen
Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Carcinoma, Ovarian Epithelial, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Endocrine System Diseases, Gonadal Disorders, Carcinoma, Bevacizumab, Enzyme Inhibitors, Antineoplastic Agents, Molecular Mechanisms of Pharmacological Action, Angiogenesis, BRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency
03/22
10/22
NCT04535427: Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

Not yet recruiting
2
144
RoW
L-arginine, Placebo
RenJi Hospital
Rheumatoid Arthritis
01/23
12/23
ANLOLA, NCT04566952: Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Recruiting
2
68
RoW
Anlotinib, FOCUS V, Olaparib, Lynparza
Xiaoxiang Chen
Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms, Neoplasms by Site, Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Carcinoma, Ovarian Epithelial, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Carcinoma, Anlotinib, PARP Inhibitors, BRCA1 Mutation, Angiogenesis, Antineoplastic Agents, BRCA2 Mutation
03/23
10/23
ROMP, NCT04582552: The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Recruiting
N/A
60
RoW
PARP inhibitors, Lynparza, Zejula
Xiaoxiang Chen
Ovarian Cancer, Clinical Marker, PARP Inhibitor
05/22
11/23
HOPEI, NCT05044091: Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Not yet recruiting
N/A
100
RoW
PARP inhibitor, Lynparza, Zejula
Xiaoxiang Chen
Ovarian Cancer, HRD, PARP Inhibitor
09/22
09/23
HOPEII, NCT05069818: Variance of HRD From Paired Ovarian Cancer

Not yet recruiting
N/A
50
RoW
Xiaoxiang Chen
Ovarian Cancer, HRD, Platinum-sensitive Ovarian Cancer
10/22
12/22

Download Options